Tegison

Active Ingredient(s): Etretinate
FDA Approved: * September 30, 1986
Pharm Company: * ROCHE
Category: Skin Care

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Tegison Overview

Etretinate (trade name Tegison) is a medication developed by Hoffmann–La Roche that was approved by the FDA in 1986 to treat severe psoriasis. It is a second-generation retinoid.[1] It was subsequently removed from the Canadian market in 1996 and the United States market in 1998 due to the high risk of birth defects. It remains on the market in Japan as Tigason. Contents 1 Pharmacology 2 Precautions 3 Side effects 4 History 5 See also 6 References Pharmacology E...

Read more Tegison Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Etretinate

Recent Tegison Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Etretinate
  • Capsule: 10mg, 25mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Etretinate or a similar ingredient: (1 result)

Related Tegison Topics:

NEW TEGISONE
New Tegisone In Psorisis Treatment...




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 23 March 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA